Dezrinitis - Instructions For Use, Indications, Doses, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Desrinitis

Instructions for use:

1. 1. Release form and composition
2. 2. Indications for use
3. 3. Contraindications
4. 4. Method of application and dosage
5. 5. Side effects
6. 6. Special instructions
7. 7. Drug interactions
8. 8. Analogs
9. 9. Terms and conditions of storage
10. 10. Terms of dispensing from pharmacies

Prices in online pharmacies:

from 361 rubles.

Buy

Desrinitis is a glucocorticosteroid (GCS) for intranasal use.

Release form and composition

Dosage form - dosed nasal spray: a homogeneous suspension of milky white [10 g (60 doses) and 18 g (140 doses) each in polyethylene bottles equipped with a dosing device, in a cardboard box 1 bottle of 10 or 18 g, 2 or 3 bottle of 18 g.].

Active ingredient: mometasone furoate monohydrate, its content in 1 dose in terms of mometasone furoate - 50 μg.

Auxiliary components: polysorbate 80, sodium citrate dihydrate, glycerol, citric acid monohydrate, benzalkonium chloride solution 500 g / l, water for injection.

Indications for use

• seasonal and year-round allergic rhinitis in adults and children from 2 years of age;
• acute sinusitis, exacerbation of chronic sinusitis in children from 12 years of age and adults, including the elderly (as an auxiliary drug in the treatment with antibacterial agents);
• polyposis of the nose in adults over 18 years old.

Also, Dezrinit is used for the prevention of moderate and severe seasonal allergic rhinitis in children from 12 years of age and adults.

Contraindications

• recent nose injury or surgery (until the wound heals);
• hypersensitivity to any component of the drug.

Application in pediatrics: Dezrinitis is not prescribed for children under 2 years old - with seasonal and allergic rhinitis, up to 12 years old - with sinusitis, up to 18 years old - with polyposis.

The drug should be used with caution in the following cases:

• airway tuberculosis (active or latent);
• bacterial, fungal and systemic viral infections (including herpes simplex with eye damage);
• local untreated infection with involvement of the nasal mucosa in the process;
• the period of pregnancy and breastfeeding;
• long-term therapy with glucocorticosteroids.

Method of administration and dosage

Desrinit is a drug for intranasal use: the spray must be injected into each nasal passage using a dosing device with which the bottle is equipped.

Before the first use, it is necessary to make about 10 test presses on the dosing device in order to establish a stereotyped drug delivery, i.e., with each press, 100 ml of suspension (50 μg of mometasone) will be ejected. A similar "calibration" must also be performed in the event of a break in using Desrinit for 14 days or more.

Shake the bottle vigorously before each use.

For allergic rhinitis, adults and adolescents over 12 years old are prescribed 2 injections into each nostril 1 time per day (total daily dose - 200 mcg). After achieving the desired effect, the dose is reduced to 1 injection in each nasal passage (total daily dose - 100 mcg). In some cases, it is possible to increase the dose to 4 injections in each nasal passage (total dose - 400 mcg). Children 2-11 years old are prescribed 1 injection in each nostril.

For the prevention of moderate and severe seasonal allergic rhinitis, it is recommended to start using the drug 4 weeks before the start of the dusting season.

With nasal polyposis, adults are prescribed 2 injections into each nasal passage 2 times a day. After reducing the severity of the symptoms of the disease, the dose is reduced to 2 injections 1 time per day.

As an auxiliary drug for sinusitis in adults and adolescents from 12 years old, Dezrinitis is prescribed 2 injections into each nostril 2 times a day. In some cases, it is possible to increase the dose up to 4 injections into each nasal passage 2 times a day (total dose - 800 mcg). After a decrease in the severity of symptoms, the dose is reduced.

Side effects

• from the nervous system: often (from ≥ 1% to <10%) in adults and children - headache; children may have sleep disturbances, aggressive behavior, anxiety, depression, psychomotor hyperactivity, growth retardation;
• allergic reactions: rarely (from ≥ 0.01% to <0.1%) - hypersensitivity reactions (including shortness of breath and bronchospasm); very rarely (<0.01%, including isolated cases) - angioedema, anaphylaxis;
• from the respiratory system: often in adults - a burning sensation in the nasal cavity, irritation of the nasal mucosa, ulceration of the nasal mucosa, pharyngitis, epistaxis, upper respiratory tract infections; very rarely - perforation of the nasal septum; often in children - sneezing, irritation of the nasal mucosa, nosebleeds;
• others: rarely - increased intraocular pressure, glaucoma, cataracts, impaired taste and smell.

With prolonged use of the drug in high doses or with the simultaneous use of several GCS, it is possible to suppress the hypothalamic-pituitary-adrenal system.

special instructions

With long-term treatment, it is necessary to periodically observe an otorhinolaryngologist in order to identify possible signs of atrophy of the nasal mucosa in time.

With prolonged use of nasal forms of GCS in high doses, systemic side effects may develop. This probability is significantly lower compared with systemic GCS. Potential systemic phenomena include: suppression of adrenal function, characteristic signs of Cushingoid, Cushing's syndrome, cataracts, glaucoma, growth retardation in children and adolescents, less often - psychological and behavioral effects, including sleep disturbances, psychomotor hyperactivity, anxiety, depression, etc. aggression, especially in children.

Children receiving Desrinitis for a long time should be monitored by a pediatrician. In case of growth retardation, it is necessary to revise the therapy and reduce the dose to the minimum effective, which will control the symptoms of the disease.

When using the drug in doses exceeding the recommended ones, clinically significant suppression of adrenal function is possible. Patients for whom the appointment of high doses of mometasone is justified, it is recommended to consult a doctor about the possibility of additional use of systemic GCS during periods of stress or elective surgery.

With the development of a local fungal infection of the nose / pharynx, the drug is canceled and specific therapy is prescribed.

Also, treatment should be discontinued in case of persistent irritation of the mucous membrane of the nasal cavity and pharynx.

Patients who are transferred to Dezrinitis after prolonged therapy with systemic GCS should be under constant medical supervision, since the cancellation of the latter can lead to the development of adrenal insufficiency, requiring appropriate measures.

During the transition from systemic corticosteroids to mometasone, some patients may experience withdrawal symptoms, for example, fatigue, muscle and / or joint pain, depression. In such cases, the doctor should convince the patient that it is advisable to continue using Dezrinit.

Also, when switching to mometasone from systemic corticosteroids, already existing allergic diseases may be revealed, which were masked by corticosteroids of systemic action, for example, allergic conjunctivitis and eczema.

The safety and effectiveness of mometasone in cystic fibrosis-related polyps, unilateral polyps, and polyps that completely obstruct the nasal cavity have not been studied. Bleeding and unilateral irregular polyps should be examined additionally.

In patients receiving GCS, immune reactivity is reduced, so they have an increased risk of infection when they come into contact with patients with certain infectious diseases (for example, measles or chickenpox). If such contact has occurred, you must consult a doctor.

No studies have been conducted on the effect of intranasal mometasone on reaction rate and ability to concentrate.

Drug interactions

With the simultaneous use of loratadine, a change in its concentration in the blood plasma does not occur, however, the presence of mometasone in the plasma is not determined even at the minimum concentration.

Interaction studies of mometasone with other drugs have not been conducted.

Analogs

An analogue of Dezrinit is Nazonex.

Terms and conditions of storage

Keep out of reach of children at temperatures up to 25 ° C, do not freeze.

Shelf life - 2 years, after the first opening of the bottle - 2 months.

Terms of dispensing from pharmacies

Dispensed by prescription.

Desrinitis: prices in online pharmacies

Drug name Price Pharmacy

Desrinitis 50 mcg / dose 140 doses nasal spray dosed 18 g 1 pc. 361 RUB Buy

Desrinit nasal spray. 50mcg / dose 140 doses 18g 369 r Buy

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!